| Added by | pmartino |
|---|---|
| Group name | EquipePM |
| Item Type | Journal Article |
| Title | Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis |
| Creator | Alyami et al. |
| Author | Mohammad Alyami |
| Author | Olivia Sgarbura |
| Author | Delphine Cabelguenne |
| Author | Laurent Villeneuve |
| Author | Denis Pezet |
| Author | Olivier Glehen |
| Author | Naoual Bakrin |
| Author | Guillaume Passot |
| Abstract | BACKGROUND: PIPAC is a recent approach for intraperitoneal chemotherapy with promising results for patients with peritoneal carcinomatosis (PC). We aimed to evaluate the postoperative outcome of PIPAC in patients with non-resectable PC during our initial experience of the technique. METHODS: All patients who underwent PIPAC for non-resectable PC in three centers were analyzed regarding postoperative outcomes. RESULTS: Seventy-three patients underwent 164 PIPAC. PC was from colorectal, gastric, ovarian, malignant mesothelioma, pseudomyxoma peritonei or other origins in 20, 26, 13, 8, 1 and 5 patients respectively. Forty-five (62%), 31 (42%), 8 (11%), 6 (8%), 1 (1%) patients underwent a second, third, fourth, fifth, and sixth PIPAC respectively. At the time of the first PIPAC, the median PCI was 17 (1-39), 57 patients presented with symptomatic PC (pain: 33; ascites: 35; transit disorder like diarrhea and constipation: 11). PCI improved in 64.5% of patients, 63.5% of patients presented with complete disappearance of symptoms. Major complications occurred as the outcome of 16 PIPAC (9.7%) and 5 (6.8%) patients died within 30 days of the PIPAC procedure. Rate of mortality and major complications 40% and 62% respectively occurred in first 20 treated patients. For 64 (88%) patients, systemic chemotherapy was associated with PIPAC and could be administered after PIPAC with a median delay of 14 days (2-28). CONCLUSIONS: Implementing a PIPAC program in association with systemic chemotherapy is feasible and is associated with a risk of postoperative morbidity, even in teams highly experienced in PC management and requires a learning curve in patient selection. |
| Publication | European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology |
| Volume | 43 |
| Issue | 11 |
| Pages | 2178-2183 |
| Date | Nov 2017 |
| Journal Abbr | Eur J Surg Oncol |
| Language | eng |
| DOI | 10.1016/j.ejso.2017.09.010 |
| ISSN | 1532-2157 |
| Library Catalog | PubMed |
| Extra | IMPACT: 3.060 PMID: 28964609 |
| Tags | Adult, Aerosols, Aged, Antineoplastic Agents, Cisplatin, clinic, Doxorubicin, Female, France, HIPEC, Humans, Injections, Intraperitoneal, Male, Middle Aged, Peritoneal metastasis, Peritoneal Neoplasms, Pressure, Prospective Studies, Treatment Outcome |
| Date Added | 2018/07/20 - 09:38:38 |
| Date Modified | 2021/03/05 - 10:44:35 |
Institut de Recherche en Cancérologie de
